Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendous...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant modalities of treatment are needed. Immunotherapy is potentially a very promising therapeutic modality for further development. Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against a unique CD38 epitope. It induces tumor-cell killing through several immunological mechanisms. It has shown a favorable safety profile as monotherapy and significant single-agent activity in relapsed/refractory myeloma. It has also demonstrated strong synergism with lenalidomide and bortezomib. The potential of this agent, together with its pharmacokinetics, mode of action, early efficacy, and safety data will be detailed in this review. Keywords: daratumumab, myeloma, monoclonal |
|---|